Roberts Glore & Co. Inc. IL Makes New $1.25 Million Investment in Gilead Sciences, Inc. $GILD

Roberts Glore & Co. Inc. IL bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund bought 9,885 shares of the biopharmaceutical company’s stock, valued at approximately $1,249,000.

A number of other large investors also recently made changes to their positions in GILD. Persistent Asset Partners Ltd bought a new stake in shares of Gilead Sciences in the 2nd quarter valued at about $25,000. Strategic Investment Solutions Inc. IL bought a new position in Gilead Sciences during the 4th quarter worth approximately $25,000. Vermillion & White Wealth Management Group LLC boosted its stake in Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 85 shares during the last quarter. Quattro Advisors LLC acquired a new position in Gilead Sciences during the fourth quarter valued at approximately $26,000. Finally, Wealth Preservation Advisors LLC increased its stake in Gilead Sciences by 60.0% in the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 81 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. Rothschild & Co Redburn reduced their price target on shares of Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Weiss Ratings cut shares of Gilead Sciences from a “buy (b-)” rating to a “hold (c-)” rating in a research report on Tuesday, August 11th. Needham & Company LLC reiterated a “buy” rating and set a $170.00 target price on shares of Gilead Sciences in a report on Wednesday, August 5th. Maxim Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a report on Wednesday, May 20th. Finally, Royal Bank Of Canada raised their price target on Gilead Sciences from $120.00 to $123.00 and gave the stock a “sector perform” rating in a research report on Wednesday, August 5th. Twenty-four equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $158.04.

Gilead Sciences Trading Up 1.4%

GILD opened at $148.77 on Wednesday. The stock has a market capitalization of $184.47 billion, a P/E ratio of -55.72 and a beta of 0.32. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. Gilead Sciences, Inc. has a 12 month low of $108.46 and a 12 month high of $157.29. The firm’s fifty day simple moving average is $132.85 and its 200 day simple moving average is $136.59.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. The firm had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The company’s revenue was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.01 EPS. As a group, research analysts anticipate that Gilead Sciences, Inc. will post -0.5 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be given a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently -122.85%.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the completion of the transaction, the insider directly owned 118,234 shares of the company’s stock, valued at $16,273,727.76. This trade represents a 19.15% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the completion of the sale, the chief executive officer owned 592,133 shares in the company, valued at $77,160,851.23. This trade represents a 2.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 87,000 shares of company stock worth $11,562,960. Insiders own 0.30% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.